Skip to main content
. 2024 Aug 12;22(6):771–781. doi: 10.1007/s40258-024-00904-1

Fig. 2.

Fig. 2

Monthly expenditure on liraglutide, dupilumab and calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) under the various drug reimbursement arrangements. These figures are exclusive of confidential rebates for all products, and inclusive of VAT and fees for liraglutide, but exclusive of VAT and fees for dupilumab and CGRP mAbs